Related Experiment Videos
[Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium]
1Department of Clinical Laboratory, Toyama Medical and Pharmaceutical University Hospital.
Abstract:
In vitro antibacterial activities of imipenem/cilastatin sodium (imipenem) and other beta-lactams against clinically isolated 353 bacterial strains were investigated. The results obtained in this study are summarized as follows: 1. Imipenem (IPM) showed potent antibacterial activities against Gram-positive cocci such as Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Streptococcus agalactiae. 2. IPM had inferior or equivalent antibacterial activities to beta-lactams against clinically isolated Enterobacteriaceae, that is, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae, Enterobacter aerogenes and Proteus spp. 3. IPM showed potent antibacterial activities against clinically isolated Pseudomonas aeruginosa, Acinetobacter anitratus but not against Xanthomonas maltophilia.
Insights
Imipenem/cilastatin sodium demonstrated strong in vitro antibacterial activity against Gram-positive cocci and Pseudomonas aeruginosa. However, its effectiveness was comparable or inferior to other beta-lactams against Enterobacteriaceae.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Context:
- Antibiotic resistance is a growing global health concern.
- Beta-lactam antibiotics are widely used to treat bacterial infections.
- Imipenem/cilastatin sodium is a broad-spectrum carbapenem antibiotic.
Purpose:
- To evaluate the in vitro antibacterial spectrum of imipenem/cilastatin sodium.
- To compare its activity against clinically isolated bacterial strains with other beta-lactams.
Summary:
- Imipenem/cilastatin sodium exhibited potent activity against Gram-positive cocci (Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Streptococcus agalactiae).
- It showed potent activity against Pseudomonas aeruginosa and Acinetobacter anitratus.
- Its activity against Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae) was inferior or equivalent to other beta-lactams.
- Imipenem/cilastatin sodium was not effective against Xanthomonas maltophilia.
Impact:
- Provides valuable data for clinicians selecting appropriate antibiotic therapy.
- Highlights the differential activity of imipenem/cilastatin sodium against various bacterial pathogens.
- Informs strategies for combating antibiotic resistance through appropriate drug utilization.